You are here:

Archived: Rasagiline 1mg tablet (Azilect®)


Following a full submission.

Rasagiline (Azilect) is not recommended for use within NHS Scotland for the treatment of idiopathic Parkinson’s disease as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Rasagiline reduces off-time in patients with Parkinson’s disease and end of dose fluctuations on levodopa, similar to reductions shown with the less effective of two currently marketed catechol-O-methyl transferase inhibitors. However, there are no comparative data with the other monoamine oxidase-B inhibitor, which is less expensive. The economic case has not been demonstrated.

Drug Details

Drug Name: Rasagiline 1mg tablet (Azilect®)
SMC Drug ID: 255/06
Manufacturer: Lundbeck Ltd
Indication: Idiopathic Parkinsons disease as adjunct therapy
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 March 2006

Current Advice

Resubmission 11 December 2006